

Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A combination comprising
 - (i) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile, also named TMC278, or a stereoisomeric form thereof; or a pharmaceutically acceptable salt thereof; ~~and or a prodrug thereof; and~~
 - (ii) ~~a nucleoside reverse transcriptase inhibitor and/or a nucleotide reverse transcriptase inhibitor~~ a tenofovir or its prodrug tenofovir disoproxil fumarate; and (iii) emtricitabine; wherein said TMC278, said tenofovir its prodrug tenofovir disoproxil fumarate and said emtricitabine ~~and the nucleotide reverse transcriptase inhibitor and the nucleoside reverse transcriptase inhibitor~~ are present in therapeutically effective amounts ~~HIV inhibitors at a dose that can be administered once daily to treat HIV.~~
2. Canceled.
3. Canceled.
4. Canceled.
5. Canceled.
6. (Previously Presented) The combination according to claim 1, wherein TMC278 occurs in its E-isomeric form.
7. Canceled.
8. Canceled.

9. Canceled.
10. Canceled.
11. Canceled.
12. Canceled.
13. Canceled.
14. Canceled.
15. Canceled.
16. Canceled.
17. Canceled.
18. Canceled.
19. (Previously Presented) The combination according to claim 1 wherein weight ratio of each couple of components of the triple combination taken on a daily basis may vary in a range from 1/4 to 4/1.
20. (Previously Presented) A product containing a combination as claimed in claim 1 as a combined preparation for simultaneous, separate or sequential use against HIV infection.
21. (Previously Presented) A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a combination as claimed in claim 1.
22. Canceled.

23. Canceled.

24. (Previously Presented) A method of preventing HIV infection comprising administering the combination as claimed in claim 1.

Please add claims 25-29 as follows:

25. (New) A kit, comprising the combination of claim 1 packaged with instructions for use.

26. (New) The combination of claim 1, wherein said TMC278, said tenofovir or its prodrug tenofovir disoproxil fumarate and said emtricitabine are each in separate pharmaceutically acceptable carriers.

27. (New) The combination of claim 26, wherein said pharmaceutically acceptable carrier is selected from the group consisting of tablets, capsules, parenteral compositions, injectable solutions, and injectable suspensions.

28. (New) The combination of claim 1, wherein said TMC278, said tenofovir or its prodrug tenofovir disoproxil fumarate and said emtricitabine are together in a single pharmaceutically acceptable carrier.

29. (New) The combination of claim 28, wherein said pharmaceutically acceptable carrier is selected from the group consisting of tablets, capsules, parenteral compositions, injectable solutions, and injectable suspensions.